Meyers B J F, van Ojen R L
Universitair Medisch Centrum Utrecht, Rudolf Magnus Instituut voor Neurowetenschappen, afd. Psychiatrie, Heidelberglaan 100, 3584 CX Utrecht.
Ned Tijdschr Geneeskd. 2004 Aug 28;148(35):1738-41.
In 3 patients, 2 women aged 21 and 65 and a man aged 60, admitted for the treatment of B-cell lymphoma, trauma caused by a traffic accident and Kahler's disease respectively, hypoactive delirium, apathy of unknown origin and depressive disorder or adjustment disorder with depressive mood ('demoralisation') were seen and caused somatic recovery to be compromised. The consulting psychiatrist prescribed methylphenidate with good results. They formed part of a group of 34 patients who were given methylphenidate on these indications over a period of 12 months. These indications are not among the accepted indications for this drug. In the literature, the beneficial use of psychostimulants in somatic illness has been described almost exclusively in palliative care and case reports of other somatically-ill patients with a poor prognosis. No reports were found on the effects of methylphenidate used for treatment of patients with hypoactive delirium nor were guidelines for its use in somatically-ill patients with a good prognosis. A randomised clinical trial to substantiate these reported findings is warranted.
3例患者,分别为21岁和65岁的女性以及60岁的男性,因B细胞淋巴瘤、交通事故所致创伤和卡勒氏病入院治疗,出现了活动减退性谵妄、不明原因的淡漠以及抑郁障碍或伴抑郁情绪的适应障碍(“士气低落”),这些情况影响了躯体康复。会诊精神科医生开了哌醋甲酯,效果良好。他们是在12个月内因这些适应证接受哌醋甲酯治疗的34例患者中的一部分。这些适应证并不在该药物的公认适应证范围内。在文献中,精神兴奋剂在躯体疾病中的有益应用几乎仅在姑息治疗以及其他预后不良的躯体疾病患者的病例报告中有所描述。未发现有关哌醋甲酯用于治疗活动减退性谵妄患者效果的报告,也没有其用于预后良好的躯体疾病患者的使用指南。有必要进行一项随机临床试验来证实这些报告结果。